Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent
The single-arm CDI-SCOPE study demonstrated that treatment with REBYOTA administered by colonoscopy was safe. Only 5 treatment-emergent adverse events (TEAEs) – occurring in 9.8% (4/41) of participants – were considered possibly related to REBYOTA, all of which were mild in intensity and related to the gastrointestinal tract. Two participants withdrew consent and did not complete the 8-week follow-up assessment.
"Colonoscopies are routinely used by physicians managing patients with recurrent C. difficile infection," said Dr. Paul Feuerstadt, M.D., F.A.C.G., A.G.A.F., Yale School of Medicine and PACT-Gastroenterology Center, a lead investigator of CDI-SCOPE. "The insights gained from this investigative study point to administration via colonoscopy as a promising potential option for physicians to consider for their patients."
A second abstract from the CDI-SCOPE study reported the burden of rCDI on health-related quality of life (HRQoL) and any improvements after treatment among 73.2% (30/41) participants. Prior to REBYOTA treatment, the most experienced rCDI symptoms were diarrhea (100%, 30/30), abdominal pain (70.0%, 21/30), and fatigue or weakness (46.7%, 14/30). All participants (100%, 30/30) reported that CDI recurrence impacted their daily living, including disrupting their sleep and forcing them to be near a bathroom at all times. Most participants also said that rCDI affected their social life and relationships (96.7%, 29/30) and their emotional wellbeing (93.3%, 28/30).
Following treatment with REBYOTA, 89.7% of participants (26/29) saw an improvement in their symptoms within the first month, and more than half (51.7%, 15/29) felt an improvement within the first week. Symptom severity rating scores (0-10, none to worst) decreased significantly at Week 8 for diarrhea (from 8.9 to 1.3), abdominal pain (from 7.5 to 1.6), and fatigue (from 8.1 to 1.7).
'Recurrent CDI is a life-altering condition that many patients in our CDI-SCOPE trial called 'a literal living nightmare' that makes it impossible to function,' said Raza Ahmed, MD, Senior Director of Medical Affairs, Ferring Pharmaceuticals. 'We are proud that REBYOTA has become an important, therapy for many patients who, for too long, were stuck in an agonizing cycle of CDI recurrence. With the data we are presenting this week at DDW, Ferring is continuing its commitment to supporting patients living with rCDI and their physicians by broadening the breadth of evidence.'
A third CDI-SCOPE abstract showed that 90% of the physicians who completed the 41 colonoscopy procedures in the study had a 'positive' or 'very positive' experience across all aspects of administration, including the material preparation time and ease of passage through the colonoscope. One investigator reported their experience as 'somewhat negative' citing difficulty with connecting REBYOTA to the colonoscope. All 39 patients who completed 8-week visits were assessed by the physicians as either having 'much improved' or 'very much improved' on the clinical global impression – improvement scale (CGI-I).
Additional Data from PUNCH™ Clinical Program
Along with the data from CDI-SCOPE, Ferring also reported two analyses with data from the PUNCH™ clinical trial program. This included:
Results from an integrated safety analysis of five clinical trials (n=1192) demonstrating a favorable safety profile with REBYOTA across all trials in the development program, including in participants with inflammatory bowel disease (IBD) and immunocompromising comorbidities. TEAEs were reported in 70.9% of patients who received REBYOTA, most of which were mild or moderate in severity and related to the gastrointestinal tract. Serious TEAEs were reported in 14.3% of patients receiving REBYOTA, most of which were related to rCDI and/or preexisting conditions, with few events (<1%) being considered possibly related to treatment. There was no clustering of serious TEAEs, including in comorbid subgroups.
This new exploratory analysis of the PUNCH™ CD3 trial in which improvements in HRQoL were associated with changes in microbiome and metabolome composition. In a previous exploratory analysis, patients who responded to REBYOTA vs. placebo had a healthier gut microbiome composition with an increase in the relative abundance of beneficial gut microbiota (Bacteroidia and Clostridia) and a decrease in other bacteria (Gammaproteobacteria and Bacilli). This new analysis found that the greatest improvements in HRQoL – as measured using the disease-specific C. difficile Quality of Life Survey (Cdiff32), which examines physical, mental and social domains – were associated with the mental health domain, with the largest improvements associated with higher levels of Bacteroidia and Clostridia and lower levels of other bacteria.
To learn more about REBYOTA and other information, please visit REBYOTA.com or www.REBYOTAHCP.com.
About C. diff infection
C. diff infection is a serious and potentially deadly infection that impacts people across the globe. The C. diff bacterium causes debilitating symptoms, such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea and colitis (an inflammation of the colon). 1 C. diff infection can be the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system. 2,3 It has been estimated that up to 35% of C. diff infection cases recur after initial diagnosis and people who have had a recurrence are at significantly higher risk of further infections. 4,5,6,7 After the first recurrence, it has been estimated that up to 65% of patients may develop a subsequent recurrence. 6,7 Antibiotics – the current standard of care for treatment of C. diff infection – treat the disease but can also be a contributing factor to the cycle of recurrence. 1
About REBYOTA
REBYOTA is a pre-packaged, single-dose 150 mL microbiota suspension for rectal administration consisting of a liquid mix of up to trillions of live microbes – including Bacteroides. REBYOTA is delivered directly to the gut microbiome and is administered by a healthcare professional in one visit.
INDICATION
REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.
IMPORTANT SAFETY INFORMATION
You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.
Please click to see the full Prescribing Information.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. The company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn, and X.
About DDW 2025
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
References:
Centers for Disease Control and Prevention. What is C. diff? 7 Sep. 2022. Available at: https://www.cdc.gov/c-diff/about/index.
Centers for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report: Clostridioides difficile. 23 Nov. 2021. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf.
Feuerstadt P, et al. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis. J Med Econ. 2020;23(6):603-609.
Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743.
Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021 Jul;27(7):828-838. doi: 10.18553/jmcp.2021.20395. Epub 2021 Mar 11.
Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18 (Suppl. 6): 21–27.
Smits WK, et al. Clostridium difficile
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the achievement of a key milestone by the clinical care team at Stanford Health Care, which has surpassed 100 cases for CellTolerance tests using the Cellvizio platform for patients with suspected food intolerance. An estimated 12% of the U.S. population suffers from IBS, and in several clinical studies using pCLE, it has been proven that more than 50% of those patients could suffer from food intolerances that can only be characterized by the real-time visualization of the intestinal barrier with Cellvizio during a food challenge. Linda Nguyen, M.D., Interim Chief, Gastroenterology & Hepatology and Clinical Professor of Medicine, Laura Pace, M.D., Clinical Assistant Professor of Medicine, and Sean Spencer, M.D. Ph.D., Instructor of Medicine, are leading the team of health care providers who are helping IBS patients end the circular loop of trying and repeatedly failing to identify and address the cause of their food-related IBS symptoms. 'With every CellTolerance test, we are using this cutting-edge technology to provide our patients with gut-specific, personalized answers. Reaching our first 100 cases is not just a milestone for our team, but a beacon of hope for all of our patients struggling with food intolerances. This program is a game-changer, and I am incredibly proud of our team for leading the charge in this new era of digestive health," said Dr. Sean Spencer at Stanford Medicine. Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated:"CellTolerance is bringing answers to the millions of patients seeking resolution of their food-related IBS symptoms, and I extend a huge congratulations to the team at Stanford for their work in implementing CellTolerance on the Cellvizio platform and achieving this fantastic milestone. We are seeing strong growth and adoption of CellTolerance worldwide, underscoring the unique value proposition of the CellTolerance test for physicians and the desire of patients to find a solution that truly addresses their unmet needs." *** About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Business Wire
an hour ago
- Business Wire
Scientists Discover a Simple Set of Rules That May Explain How Our Tissues Stay Organized
WILMINGTON, Del.--(BUSINESS WIRE)--Every day, your body replaces billions of cells—and yet, your tissues stay perfectly organized. How is that possible? 'Just like we have a genetic code that explains how our genes work, we may also have a 'tissue code' that explains how our bodies stay so precisely organized over time,' said Bruce Boman, M.D., Ph.D. Share A team of researchers at ChristianaCare's Helen F. Graham Cancer Center & Research Institute and the University of Delaware believe they've found an answer. In a new study published today in the scientific journal Biology of the Cell, they show that just five basic rules may explain how the body maintains the complex structure of tissues like those in the colon, for example, even as its cells are constantly dying and being replaced. Download photos. This research is the product of more than 15 years of collaboration between mathematicians and cancer biologists to unlock the rules that govern tissue structure and cellular behavior. 'This may be the biological version of a blueprint,' said Bruce Boman, M.D., Ph.D., senior research scientist at ChristianaCare's Cawley Center for Translational Cancer Research and faculty member in the departments of Biological Sciences and Mathematical Sciences at the University of Delaware. 'Just like we have a genetic code that explains how our genes work, we may also have a 'tissue code' that explains how our bodies stay so precisely organized over time.' Math Meets Medicine The researchers used mathematical modeling—essentially, creating a computer simulation of how cells behave—to see if a small number of rules could account for the highly organized structure of the lining of the colon. That's an ideal place to study: cells in the colon renew every few days, but the overall shape and structure stays remarkably stable. After running many simulations and refining their models, the team identified five core biological rules that appear to govern the structure and behavior of cells: Timing of cell division. The order in which cells divide. The direction cells divide and move. How many times cells divide. How long a cell lives before it dies. 'These rules work together like choreography,' said Gilberto Schleiniger, Ph.D., professor in the University of Delaware's Department of Mathematical Sciences. 'They control where cells go, when they divide and how long they stick around—and that's what keeps tissues looking and working the way they should.' Decoding Human Tissue The researchers believe these rules may apply not just to the colon, but to many different tissues throughout the body—skin, liver, brain and beyond. If true, this 'tissue code' could help scientists better understand how tissues heal after injury, how birth defects happen and how diseases like cancer develop when that code gets disrupted. Boman explained it this way: 'Your tissues don't just grow and shrink randomly. They know what they're supposed to look like, and they know how to get back to that state, even after damage. That level of precision needs a set of instructions. What we've found is a strong candidate for those instructions.' This work also has important implications for the Human Cell Atlas, a global scientific collaboration working to map every cell type in the human body. While the Atlas aims to catalog what each cell is and what it's doing at a given moment, this new research offers a dynamic framework for understanding how those cells stay organized over time. By identifying simple, universal rules that govern cell behavior and tissue structure, the findings could help guide future efforts to not only describe cells, but predict how they behave in health and disease. Implications for Disease and Discovery One reason the team turned to mathematical models, rather than traditional biology experiments, is that it's extremely difficult to observe how every single cell in a tissue behaves in real time. But with computer models, researchers can run simulations that reveal patterns and dynamics hidden from view. This kind of collaboration between biology and math reflects a broader shift in how scientists approach complex problems. It also aligns with national priorities: the National Science Foundation's ' Rules of Life ' initiative challenges researchers to uncover the fundamental principles that govern living systems. This study is a strong step in that direction. Next steps for the team include testing the model's predictions experimentally, refining it with additional data and exploring its relevance to cancer biology—especially how disruptions to the tissue code may lead to tumor growth or metastasis. 'This is just the beginning,' said Schleiniger. 'Once you can identify the rules, you can begin to ask entirely new questions, and maybe even learn how to fix what's gone wrong.' Funding for this project was provided by the National Institutes of Health, the National Science Foundation, The Lisa Dean Moseley Foundation, the Delaware Bioscience Center for Advanced Technology (CAT) and the UNIDEL Graduate Research Fellowship. About ChristianaCare Headquartered in Wilmington, Delaware, ChristianaCare is one of the country's most dynamic health care organizations, centered on improving health outcomes, and innovating to make high-quality care more accessible, equitable and affordable. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,430 beds), a freestanding emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women's health. It also includes the pioneering Gene Editing Institute. ChristianaCare is nationally recognized as a great place to work, rated by Forbes as one of the nation's best employers for diversity and inclusion. ChristianaCare is rated by Newsweek as one of the World's Best Hospitals and is continually ranked among the best in the U.S. in national quality and safety ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care. About the Cawley Center for Translational Cancer Research The Cawley Center for Translational Cancer Research (CTCR) at the Helen F. Graham Cancer Center & Research Institute moves research from the laboratory bench to the patient's bedside by applying basic science toward potential therapies. The Cawley CTCR is where scientists study the molecular causes of cancer and tissue engineering, all targeted to better treatment for patients. Groundbreaking findings and current studies at the center are helping to prevent, better detect and stop the growth of many cancers — and as a result reducing cancer incidence and mortality rates in Delaware and beyond. About the University of Delaware The University of Delaware traces its roots to 1743, making it the seventh-oldest higher education institution in the country. UD's tradition of excellence continues today in both the classroom and the laboratory, with consistent ranking among the top 40 public universities. Beyond its Georgian-inspired main campus in Newark, Delaware, UD has locations in Wilmington, Dover, Georgetown and Lewes, in addition to a growing online learning environment. UD is a state-assisted, privately governed institution and one of a select group to hold the triple Land Grant, Sea Grant and Space Grant designation. UD is classified nationally as a Research 1 (R1) university for its very high research activity and doctorate production, a designation held by less than 5% of U.S. colleges and universities. UD also is recognized as a Community Engaged University for its long tradition of applying knowledge and creativity to the critical challenges facing communities in Delaware and around the world. About the University of Delaware's Department of Mathematical Sciences The University of Delaware's Department of Mathematical Sciences offers a diverse suite of programs – from actuarial science and applied mathematics to mathematics‑and‑economics, mathematics education, and quantitative biology – designed to develop both deep theoretical insight and practical problem-solving skills. The department's vibrant community of scholars and educators is anchored by the Mathematical Sciences Learning Lab and the Center for Applications of Mathematics in Medicine. Faculty and students collaborate on cutting‑edge research across pure and applied mathematics – exploring topics such as algebra, topology, probability, and graph theory – and join forces with colleagues in computer science, data science, engineering, biology, and neuroscience. About the University of Delaware's Department of Biological Sciences The Department of Biological Sciences at the University of Delaware is a dynamic and interdisciplinary community of scholars, researchers, and educators. With a proud legacy of academic excellence and a strong track record of external research funding, the department offers an exceptional undergraduate experience that blends classroom instruction, problem-based learning, hands-on lab training, and mentored research in faculty labs. This comprehensive approach equips students with the skills and knowledge to thrive in a wide range of careers or advanced studies. At the graduate level, the department focuses on uncovering the molecular mechanisms of life, using bacterial, invertebrate, and vertebrate model systems to advance understanding and improve human health and society. Our collaborative teaching and research environment spans molecular biology and genetics, developmental biology, cell and tissue physiology, microbiology, and science education – creating a vibrant, inclusive, and impactful scientific community.
Business Wire
an hour ago
- Business Wire
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR ® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC), focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy. This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments. By leveraging our RADR® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided... Share In a peer-reviewed study published in Frontiers in Oncology, Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module. 1 Transforming Cancer Combination Therapy Development The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer (TNBC). "This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments," said Panna Sharma, CEO & President of Lantern Pharma. "By leveraging our RADR ® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods." The module integrates genomic, transcriptomic, and clinical data to predict synergistic drug interactions, optimize therapeutic outcomes, and identify biomarker-defined patient subpopulations likely to respond to specific combinations. This data-driven approach directly informed the design of Lantern's FDA-cleared Phase 1B/2 trial in TNBC for LP-184 and olaparib, with potential to improve response rates and reduce toxicity. Key insights from the study powering the AI module include: Non-PARP Inhibitor Promise: Non-PARP DDRi combinations, particularly WEE1 inhibitors like adavosertib with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials, with strong efficacy in TP53-mutated cancers, directly informing future trial design. Biomarker-Driven Success: Biomarkers such as TP53 mutations and HRD signatures were critical predictors of response, enabling patient stratification to maximize efficacy. Toxicity Mitigation: The use of novel formulations like liposomal doxorubicin in combination regimens reduced cardiotoxicity, providing a safer backbone for combination strategies. Emerging Trends: The analysis emphasizes the patterns in treatment effectiveness, safety, and emerging trends across various cancer types and discusses the potential of biomarkers to guide treatment selection and improve patient outcomes. The module's multi-agentic framework integrates specialized AI agents for data aggregation, drug classification, predictive modeling, biomarker identification, and optimization, creating a dynamic system that is planned to evolve along with new data. The system's continuous learning capability ensures adaptability, enabling Lantern to refine regimens and accelerate future trials across diverse cancer indications. The company is exploring licensing and commercialization opportunities to expand the application of this technology, further revolutionizing combination therapy development. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR ® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes. Please find more information at: Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 1 Fontenot R, Biyani N, Bhatia K, Ewesuedo R, Chamberlain M and Sharma P (2025) Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. Front. Oncol. 15:1577468. doi: 10.3389/fonc.2025.1577468
